Title |
Long‐acting beta2‐agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid
|
---|---|
Published in |
Cochrane database of systematic reviews, January 2007
|
DOI | 10.1002/14651858.cd001385.pub2 |
Pubmed ID | |
Authors |
E. Haydn Walters, Peter G Gibson, Toby J Lasserson, Julia AE Walters |
Abstract |
Asthma is a common respiratory disease among both adults and children and short acting inhaled beta-2 agonists are used widely for 'reliever' bronchodilator therapy. Long acting beta-2 agonists (LABA) were introduced as prospective 'symptom controllers' in addition to inhaled corticosteroid 'preventer' therapy (ICS). In this updated review we have included studies in which patients were either not on ICS as a group, or in which some patients, but not all, were on ICS to complement previous systematic reviews of studies where LABA was given in patients uniformly receiving ICS. We have focussed particularly on serious adverse events, given previous concerns about potential risks, especially of death, from regular beta-2 agonist use. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 50% |
Ecuador | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Colombia | 1 | <1% |
United Kingdom | 1 | <1% |
Denmark | 1 | <1% |
Japan | 1 | <1% |
United States | 1 | <1% |
Unknown | 226 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 41 | 18% |
Student > Ph. D. Student | 23 | 10% |
Researcher | 22 | 10% |
Student > Bachelor | 20 | 9% |
Student > Doctoral Student | 13 | 6% |
Other | 34 | 15% |
Unknown | 78 | 34% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 80 | 35% |
Nursing and Health Professions | 30 | 13% |
Psychology | 8 | 3% |
Agricultural and Biological Sciences | 7 | 3% |
Social Sciences | 7 | 3% |
Other | 15 | 6% |
Unknown | 84 | 36% |